Bommer J, Kugel M, Schwöbel B, Ritz E, Barth H P, Seelig R
Department of Internal Medicine, University of Heidelberg, FRG.
Nephrol Dial Transplant. 1990;5(3):204-7. doi: 10.1093/ndt/5.3.204.
In seven male haemodialysis patients, living with a constant sexual partner, sexual life (self-administered questionnaire) and sex hormones were evaluated before and 3 or 10 months after commencement of recombinant human erythropoietin (rHuEpo) therapy respectively. Haematocrit increased from 22.2 +/- 2.1% to 30.6 +/- 1% with a maintenance dose of 140 +/- 55 U/kg per week. Two patients were hypertensive before and after rHuEpo therapy; antihypertensive medication was kept constant during the study. Self-reported sexual function improved in four of seven patients, including libido and erection. This was paralleled by improved indices of wellbeing (physical fitness, mental alertness). In contrast, serum values of sexual hormones (testosterone or oestradiol) and of basal and stimulated (LHRH/TRH), prolactin and LH, and FSH were not significantly changed during rHuEpo therapy.
对7名维持固定性伴侣的男性血液透析患者，分别在重组人促红细胞生成素（rHuEpo）治疗开始前以及治疗3个月或10个月后，对其性生活（通过自行填写问卷）和性激素进行了评估。通过每周140±55 U/kg的维持剂量，血细胞比容从22.2±2.1%增至30.6±1%。两名患者在rHuEpo治疗前后均患有高血压；研究期间抗高血压药物维持不变。7名患者中有4名自我报告性功能有所改善，包括性欲和勃起功能。这与健康指标（身体素质、精神敏锐度）的改善相平行。相比之下，在rHuEpo治疗期间，性激素（睾酮或雌二醇）以及基础和刺激状态下（促性腺激素释放激素/促甲状腺激素释放激素）的催乳素、促黄体生成素和促卵泡生成素的血清值均无显著变化。
